218 related articles for article (PubMed ID: 15077178)
1. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
[TBL] [Abstract][Full Text] [Related]
2. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
3. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
Alas S; Emmanouilides C; Bonavida B
Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
6. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.
Alas S; Bonavida B
Cancer Res; 2001 Jul; 61(13):5137-44. PubMed ID: 11431352
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract][Full Text] [Related]
8. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
Bonavida B
Oncogene; 2007 May; 26(25):3629-36. PubMed ID: 17530016
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.
Weldon CB; Parker AP; Patten D; Elliott S; Tang Y; Frigo DE; Dugan CM; Coakley EL; Butler NN; Clayton JL; Alam J; Curiel TJ; Beckman BS; Jaffe BM; Burow ME
Int J Oncol; 2004 Jun; 24(6):1473-80. PubMed ID: 15138590
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
[TBL] [Abstract][Full Text] [Related]
12. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
Jazirehi AR; Bonavida B
Methods Mol Biol; 2011; 731():407-19. PubMed ID: 21516425
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
Alas S; Bonavida B
Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
[TBL] [Abstract][Full Text] [Related]
14. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
[TBL] [Abstract][Full Text] [Related]
16. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
18. Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells.
Chen TH; Kao YC; Chen BC; Chen CH; Chan P; Lee HM
Eur J Pharmacol; 2006 Jul; 541(3):138-46. PubMed ID: 16765938
[TBL] [Abstract][Full Text] [Related]
19. Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-kappaB-induced CCAAT/enhancer-binding protein delta in mouse macrophages.
Liu YW; Chen CC; Tseng HP; Chang WC
Cell Signal; 2006 Sep; 18(9):1492-500. PubMed ID: 16413748
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2.
Ji JD; Kim HJ; Rho YH; Choi SJ; Lee YH; Cheon HJ; Sohn J; Song GG
Rheumatology (Oxford); 2005 Aug; 44(8):983-8. PubMed ID: 15840591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
